AR059129A1 - Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR059129A1
AR059129A1 ARP070100022A ARP070100022A AR059129A1 AR 059129 A1 AR059129 A1 AR 059129A1 AR P070100022 A ARP070100022 A AR P070100022A AR P070100022 A ARP070100022 A AR P070100022A AR 059129 A1 AR059129 A1 AR 059129A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
cycloalkyl
substituted
halogen
Prior art date
Application number
ARP070100022A
Other languages
English (en)
Inventor
Samir Jegham
Daniel Floutard
Pierre Fraisse
Pierre Casellas
Stephane Hourcade
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR059129A1 publication Critical patent/AR059129A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compuesto de formula (1) siguiente: en la que R1 representa un átomo de hidrogeno, halogeno, un grupo alquilo (C1-8), trifluoroalquilo (C1-4), -OH, -O-alquilo (C1-8), -O-trifluoroalquilo (C1-8), -O-alquil (C1-8)-cicloalquilo (C3-10), -O- cicloalquilo(C3-10), -O-CH2-CH=CH2, -S-alquilo (C1-4); R2 representa un átomo de hidrogeno, de halogeno, un grupo -OH, alquilo (C1-8), trifluoroalquilo (C1-4), perfluoroalquilo (C1-4), ciloalquilo (C3-10), -O-alquilo (C1-8), -O-alquil (C1-8)- cicloalquilo (C3-10), -O-cicloalquilo (C3-10), -O-CH2-CH=CH2, -alquil (C1-8)-cicloalquilo(C3-8); Y representa un átomo de hidrogeno o un halogeno; p representa 2 o 3; R3 representa: a1) un grupo de formula -(CH2)a-A en la que a representa 1, 2, 3 o 4, y A se selecciona del grupo de formulas (2) en las que R7 se selecciona en el grupo constituido por alquil (C1-8)-COO-alquilo (C1-8), -CO-alquilo (C1-8) en las que el alquilo está sustituido por al menos un átomo de halogeno, -cicloalquilo (C3- 10), fenilo, -COO-cicloalquilo (C3-10), -SO2-alquilo (C1-8) en la que el alquilo está sustituido por al menos un átomo de halogeno, -SO2-fenilo en la que el fenilo está sustituido por al menos un grupo -O-alquilo (C1-8), -SO2-heteroarilo en la que el heteroarilo es un pirazol, un isoxazol o un imidazol y en la que está independientemente sustituido por al menos un grupo seleccionado entre halogeno o -alquilo (C1-8), -SO2-N((alquilo C1-8))2, -SO2-OH, -SO2-cicloalquilo (C3-10), -CO-NH(alquilo (C1-8)), -alquil (C1-8)-CN, -alquil (C1-8)-imidazol, -alquil (C1-8)-COOH, -alquil (C1-8)-COO-M+, -alquil (C1-8)-OH, -alquil (C1-8)-tetrazol, -alquil (C1-8)-CO-NH2, -alquil (C1-8)-CO-NH(alquilo (C1-8)), alquil (C1-8)-CO-NH(cicloalquilo (C3-10)), - alquil (C1-8)-CO-N(alquil (C1-8))(cicloalquilo (C3-10)), -alquil (C1-8)-CO-N(alquilo (C1-8))2, -alquil (C1-8)-CO-N(cicloalquilo (C3-10))2, en la que M+ es un cation de metal alcalino seleccionado entre Li+, Na+ y K+, y cuando hay dos sustituyentes alquilo o cicloalquilo unidos al átomo de nitrogeno, pueden ser independientemente idénticos o diferentes; a2) un grupo de formula -CO(CH2)b-A en la que b representa 01, 2, 3 o 4, y A se selecciona del grupo de formulas (2) en las que R7 es tal como se ha definido anteriormente; a3) un grupo -B en el que B se selecciona del grupo de formulas (3) en las que R7 es tal como se ha definido anteriormente; a4) un grupo de formula -(CH2)a-C en la que a representa 1, 2, 3 o 4, y C se selecciona del grupo de formulas (4) en las que: R8 se selecciona en el grupo constituido por un átomo de hidrogeno, un grupo alquilo (C1-8), alquil (C1-8)-COO-alquilo (C1-8), -CO-alquilo (C1-8) en las que alquilo (C1-8), alquil (C1-8)-COO-alquilo (C1-8), -CO- alquilo (C1-8) en las que el alquilo está sustituido por al menos un átomo de halogeno, -cicloalquilo (C3-10), fenilo, -COO-cicloalquilo (C3-10), -SO2-alquilo (C1-8) en la que el alquilo está sustituido por al menos un átomo de halogeno, -SO2-fenilo en la que el fenilo está sustituido por al menos un grupo -O-alquilo (C1-8), -SO2-heteroarilo en la que el heteroarilo es un pirazol, un isoxazol o un imidazol y en la que está de modo eventual independientemente sustituido por al menos un grupo seleccionado entre halogeno o -alquilo (C1-8), -SO2-N((alquilo C1-8))2, -SO2-OH, -SO2-cicloalquilo (C3-10), -CO-NH(alquilo(C1-8)), -alquil (C1-8)-imidazol, -alquil(C1-8)-COOH, -alquil (C1-8)-COO-M+, alquil (C1-8)-OH, -alquil (C1-8)-tetrazol, -alquil (C1-8)-CO-NH2, -alquil (C1-8)-CO-NH(alquilo(C1-8)), -alquil (C1-8)-CO-NH(cicloalquilo (C3-10)), -alquil (C1-8)-CO-N(alquil (C1-8)))(cicloalquilo (C3-10)), -alquil (C1-8)-CO-N(alquilo (C1-8))22, -alquil (C1-8)-CO-N(cicloalquilo (C3-10))2, en la que M, es un cation de metal alcalino seleccionado entre Li+, Na+ y K+, y cuando hay dos substituyentes alquilo o cicloalquilo unidos al átomo de nitrogeno, pueden ser independientemente idénticos o diferentes; -R9 se selecciona del grupo constituido por: hidroxilo, O-alquilo (C1-8), -O-trifluoroalquilo (C1-8), -O-alquil (C1-8-cicloalquilo (C3-10), -O-cicloalquilo (C3-10), -Ra, Rb, Rc y Rd son independientemente un átomo de hidrogeno o un grupo metilo, siendo al menos uno de Ra, Rb, Rc y Rd un grupo metilo; - Re, Rf, Rg y Rh son independientemente un átomo de hidrogeno o un grupo metilo, siendo al menos uno de Ra, Rb, Rc y Rd un grupo metilo; -Re, Rf, Rg y Rh son independientemente un átomo de hidrogeno o un grupo metilo; a5) un grupo de formula -CO(CH2)b-C en la que b representa 0, 1, 2, 3 o 4 y C selecciona del grupo de formulas (4) en las que -R8, R9, Ra, Rb, Rc, Rd, Re, Rf, Rg y Rh son tales como se definieron anteriormente, a6) un grupo -D en el que D se selecciona del grupo de formulas: (4) en las que - R8, R9, Ra, Rb, Rc, Rd, Re, Rf, Rg y R h son tales como se definieron anteriormente, en forma de base o de sal de adicion a un ácido, así como en forma de hidratos o de solvatos.
ARP070100022A 2006-01-06 2007-01-03 Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica AR059129A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600117A FR2895989B1 (fr) 2006-01-06 2006-01-06 Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR059129A1 true AR059129A1 (es) 2008-03-12

Family

ID=36940477

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100022A AR059129A1 (es) 2006-01-06 2007-01-03 Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica

Country Status (23)

Country Link
US (1) US7825112B2 (es)
EP (1) EP1984361A1 (es)
JP (1) JP2009525951A (es)
KR (1) KR20080082970A (es)
CN (1) CN101365698A (es)
AP (1) AP2008004568A0 (es)
AR (1) AR059129A1 (es)
AU (1) AU2007203998A1 (es)
BR (1) BRPI0706305A2 (es)
CA (1) CA2632854A1 (es)
CR (1) CR10098A (es)
DO (1) DOP2007000004A (es)
EA (1) EA200870157A1 (es)
EC (1) ECSP088574A (es)
FR (1) FR2895989B1 (es)
GT (1) GT200700002A (es)
IL (1) IL191892A0 (es)
MA (1) MA30179B1 (es)
NO (1) NO20083352L (es)
PE (1) PE20070816A1 (es)
TN (1) TNSN08242A1 (es)
TW (1) TW200738703A (es)
WO (1) WO2007077394A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2406634A1 (fr) * 1977-10-19 1979-05-18 Fabre Sa Pierre Immunostimulants derives d'amino thiazoles
WO1987001706A2 (en) 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
WO1993000342A1 (en) * 1991-06-21 1993-01-07 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
US6506751B1 (en) * 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US7132546B2 (en) * 2000-12-22 2006-11-07 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002360733A1 (en) 2001-12-31 2003-07-24 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA(imn)PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2872813B1 (fr) * 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2876692B1 (fr) * 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0519288A2 (pt) * 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
WO2008064054A2 (en) * 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor

Also Published As

Publication number Publication date
TNSN08242A1 (en) 2009-10-30
EP1984361A1 (fr) 2008-10-29
US7825112B2 (en) 2010-11-02
TW200738703A (en) 2007-10-16
PE20070816A1 (es) 2007-08-17
CR10098A (es) 2008-11-26
MA30179B1 (fr) 2009-01-02
NO20083352L (no) 2008-07-30
KR20080082970A (ko) 2008-09-12
ECSP088574A (es) 2008-07-30
BRPI0706305A2 (pt) 2011-03-22
AP2008004568A0 (en) 2008-08-31
FR2895989B1 (fr) 2010-04-30
WO2007077394A1 (fr) 2007-07-12
GT200700002A (es) 2007-08-20
US20090018117A1 (en) 2009-01-15
CA2632854A1 (fr) 2007-07-12
CN101365698A (zh) 2009-02-11
AU2007203998A1 (en) 2007-07-12
EA200870157A1 (ru) 2009-12-30
IL191892A0 (en) 2008-12-29
FR2895989A1 (fr) 2007-07-13
JP2009525951A (ja) 2009-07-16
DOP2007000004A (es) 2007-07-31

Similar Documents

Publication Publication Date Title
MA33581B1 (fr) Composition pharmaceutique contenant un dérivé de quinoléine
AR118673A1 (es) Procedimiento para la preparación de derivados de oxadiazol microbiocidas
RU2007131274A (ru) Замещенные пиразолопиридины, композиции, содержащие их, способ получения и применение
NI201000124A (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
RU2011137457A (ru) Пестицыдные композиции
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
NO20082917L (no) Oksadiazolderivater med CRTH2-reseptoraktivitet
AR051780A1 (es) Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
CO5680449A2 (es) Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
AR107633A1 (es) Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
HRP20080052T3 (hr) Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala
AR094123A1 (es) Compuesto triciclicos
CO6190582A2 (es) Derivados de heteroarilamida
EA200401613A1 (ru) Лекарственное средство для лечения рака
AR082696A1 (es) Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos
AR057894A1 (es) Derivados de tiofeno
AR077066A1 (es) Derivados de tiazolilpiperidina como fungicidas, procedimientos para su preparacion e intermediarios de sintesis utilizados en los mismos.
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR071592A1 (es) Fenoxibenzamidas sustituidas
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
AR057980A1 (es) Derivados de la 1- amino-ftalazina sustituida, su preparacion y composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure